Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Cetuximab + Chemotherapy in 1L R/M HNSCC
NCT05673577Phase 2Completed
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fudan University. Started Mar 2023; status: completed.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05673577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673577.